抗体药物偶联物：进展、陷阱与前景。
Antibody drug conjugates: Progress, pitfalls, and promises.
作者信息
Mukherjee Anubhab, Waters Ariana K, Babic Ivan, Nurmemmedov Elmar, Glassy Mark C, Kesari Santosh, Yenugonda Venkata Mahidhar
机构信息
Drug Discovery and Nanomedicine Research Program, CA-90404, USA.
Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Pacific Neuroscience Institute, Providence Saint John's Health Center, Santa Monica, CA-90404, USA.
出版信息
Hum Antibodies. 2019;27(1):53-62. doi: 10.3233/HAB-180348.
Antibody drug conjugates (ADCs) represent a promising and an efficient strategy for targeted cancer therapy. Comprised of a monoclonal antibody, a cytotoxic drug, and a linker, ADCs offer tumor selectively, reduced toxicity, and improved stability in systemic circulation. Recent approvals of two ADCs have led to a resurgence in ADC research, with more than 60 ADCs under various stages of clinical development. The therapeutic success of future ADCs is dependent on adherence to key requirements of their design and careful selection of the target antigen on cancer cells. Here we review the main components in the design of antibody drug conjugates, improvements made, and lessons learned over two decades of research, as well as the future of third generation ADCs.
抗体药物偶联物（ADCs）是一种很有前景且高效的靶向癌症治疗策略。ADCs由单克隆抗体、细胞毒性药物和连接子组成，可实现肿瘤选择性、降低毒性并提高在体循环中的稳定性。最近两款ADCs的获批引发了ADCs研究的复兴，目前有60多种ADCs正处于临床开发的不同阶段。未来ADCs的治疗成功取决于是否符合其设计的关键要求以及对癌细胞上靶抗原的精心选择。在此，我们综述了抗体药物偶联物设计中的主要组成部分、取得的改进、二十多年研究中的经验教训以及第三代ADCs的未来发展。
Zotero 插件